- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Nurix Therapeutics Inc (NRIX)
Nurix Therapeutics Inc stock price live, this page displays NASDAQ NRIX stock exchange data. View the NRIX premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Nurix Therapeutics Inc real time stock price chart below.
What Is the Nurix Therapeutics Inc Stock Price Today?
The Nurix Therapeutics Inc stock price today is 9.54.
What Is the Stock Symbol for Nurix Therapeutics Inc?
The stock symbol for Nurix Therapeutics Inc is ""NRIX.""
What Stock Exchange Does Nurix Therapeutics Inc Trade On?
Nurix Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Nurix Therapeutics Inc a Good Stock to Buy?
Determining whether Nurix Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the NRIX quote. (ISIN: US67080M1036)
What Is the Nurix Therapeutics Inc Stock Price Today?
The Nurix Therapeutics Inc stock price today is 9.54.
What Is the Stock Symbol for Nurix Therapeutics Inc?
The stock symbol for Nurix Therapeutics Inc is ""NRIX.""
What Stock Exchange Does Nurix Therapeutics Inc Trade On?
Nurix Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Nurix Therapeutics Inc a Good Stock to Buy?
Determining whether Nurix Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the NRIX quote. (ISIN: US67080M1036)
NASDAQ
Currency in USD
9.54
+0.13(+1.33%)
Real-time Data·
Fair Value
An estimate of a Nurix's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
9.44
9.65
52 wk Range
8.18
29.56
NRIX Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
NRIX is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Nurix's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
9.449.65
52 wk Range
8.1829.56
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
NRIX Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Nurix's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
29.83
Upside
+212.72%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Sell
Moving Averages
Sell
Nurix Therapeutics Inc Company Profile
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader, that is in Phase 1A clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1A clinical trials to treat immuno-oncology indications. It is also developing NX 0479/GS 6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.
Nurix Therapeutics Inc SWOT Analysis
Promising Pipeline | Explore Nurix's innovative protein degradation platform and its lead candidate bexobrutideg, showing encouraging results in CLL and NHL clinical trials |
Financial Health | Despite operating losses, Nurix maintains a strong cash position of $609.6 million, funding operations into 2027 with analyst targets ranging from $16 to $41 |
Strategic Expansion | Delve into Nurix's move beyond oncology into autoimmune diseases, potentially broadening its market reach and diversifying revenue streams |
Competitive Landscape | Learn about Nurix's partnerships with major pharmaceutical companies and how it navigates intense competition in the rapidly evolving biotechnology secto |
Compare NRIX to Peers and Sector
Metrics to compare | NRIX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNRIXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −3.5x | −1.3x | −0.6x | |
PEG Ratio | −0.32 | −0.05 | 0.00 | |
Price/Book | 1.6x | 1.7x | 2.6x | |
Price / LTM Sales | 8.1x | 8.3x | 3.3x | |
Upside (Analyst Target) | 219.1% | 272.0% | 39.1% | |
Fair Value Upside | Unlock | 27.6% | 5.4% | Unlock |
Analyst Ratings
16 Buy
2 Hold
0 Sell
Ratings:
18 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 29.83
(+212.72% Upside)
Earnings
Latest Release
Jul 09, 2025
EPS / Forecast
-0.52 / -0.714
Revenue / Forecast
44.06M / 16.90M
People Also Watch
FAQ
What Stock Exchange Does Nurix Trade On?
Nurix is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Nurix?
The stock symbol for Nurix is "NRIX."
What Is the Nurix Market Cap?
As of today, Nurix market cap is 729.33M.
What Is Nurix's Earnings Per Share (TTM)?
The Nurix EPS (TTM) is -2.60.
When Is the Next Nurix Earnings Date?
Nurix will release its next earnings report on 08 Oct 2025.
From a Technical Analysis Perspective, Is NRIX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Nurix Stock Split?
Nurix has split 0 times.
How Many Employees Does Nurix Have?
Nurix has 286 employees.
What is the current trading status of Nurix (NRIX)?
As of 29 Aug 2025, Nurix (NRIX) is trading at a price of 9.54, with a previous close of 9.41. The stock has fluctuated within a day range of 9.44 to 9.65, while its 52-week range spans from 8.18 to 29.56.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.